Extracellular Hsp90α, which participates in vascular inflammation, is a novel serum predictor of atherosclerosis in type 2 diabetes

Xinyi Ding, Chuzhen Meng, Hangming Dong, Shili Zhang, Hui Zhou, Wenchong Tan, Lei Huang, Aiping He, Jieyou Li, Jiali Huang, Wei Li, Fei Zou, MengChen Zou, Xinyi Ding, Chuzhen Meng, Hangming Dong, Shili Zhang, Hui Zhou, Wenchong Tan, Lei Huang, Aiping He, Jieyou Li, Jiali Huang, Wei Li, Fei Zou, MengChen Zou

Abstract

Introduction: Atherosclerosis is the main pathological change in diabetic angiopathy, and vascular inflammation plays an important role in early atherosclerosis. Extracellular heat shock protein 90 (eHsp90) is secreted into the serum and is involved in various physiological and pathophysiological processes. However, the specific mechanism of eHsp90 in early atherosclerosis remains unclear. This study explored the relationship between Hsp90 and diabetic lower extremity arterial disease and investigated the expression of eHsp90 in vascular endothelial cells under environmental stimulation and the function and mechanism of eHsp90α involved in diabetic atherosclerosis.

Research design and methods: One hundred and three selected patients were divided into three groups: the diabetes mellitus group (n=27), the diabetic lower extremity arterial disease group (n=46), and the diabetic critical limb ischemia group (n=30). The relationships among serum Hsp90, oxidative stress indexes, and patient outcomes and the correlations among the indexes were analyzed. H&E staining and immunohistochemistry were used to observe the vasculature of amputated feet from patients with diabetic foot. An oxidative stress endothelial injury model was established under high glucose in vitro to explore the role of eHsp90 release in atherosclerosis progression.

Results: The level of serum Hsp90 was upregulated with aggravation of diabetic vascular disease. Hsp90α was correlated with malondialdehyde to some extent and was an independent risk factor in the progression of diabetic vascular disease, with predictive ability. The expression area of Hsp90α was consistent with the area of inflammatory infiltration in the vessel lumen. Vascular endothelial cells were found to increase eHsp90α secretion under stress. Then inhibition of eHsp90α can reduce the degree of cellular inflammation and damage. Endothelial cell-conditioned medium and recombinant human Hsp90α increased monocyte migration via the low-denisity lipoprotein receptor-related protein 1 (LRP1) receptor to promote disease progression.

Conclusions: eHsp90α plays a critical role in the early inflammatory injury stage of atherosclerosis.

Trial registration number: NCT04787770.

Keywords: atherosclerosis; diabetes mellitus; early diagnosis; type 2; vascular.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Comparison and correlation analyses of serum levels of MDA, Hsp90α, Hsp90β, WCC, and CRP in the study subjects. Serum MDA (A), Hsp90α (B), and Hsp90β (C) levels were measured in the different groups. *P

Figure 2

Multivariate logistic regression model and…

Figure 2

Multivariate logistic regression model and diagnostic efficacy of Hsp90α and Hsp90β for DLEAD.…

Figure 2
Multivariate logistic regression model and diagnostic efficacy of Hsp90α and Hsp90β for DLEAD. Histopathological changes in blood vessels. Multivariate logistic regression analysis (A): a forest plot obtained from a multiple logistic regression model as OR with 95% CI. Comparing patients with DLEAD and DM, age, Hsp90α, course, and family history were independent risk factors for the development of DLEAD. Comparing patients with DCLI and DM, age, Hsp90α, Hsp90β, and course were independent risk factors for DCLI. Receiver operating characteristic analysis of the diagnostic efficacy of Hsp90α and Hsp90β for DM and DLEAD (B). Diagnostic ability to distinguish patients with DLEAD from patients with DM. HE staining (C and E) and immunohistochemistry (D and F) (40×, 100×, 200×) of Hsp90α in the blood vessels of patients with DCLI undergoing partial amputation (n=3). CHOL, cholesterol; DCLI, diabetic critical limb ischemia; DLEAD, diabetic lower extremity arterial disease; DM, diabetes mellitus; Hb, hemoglobin; Hsp90, heat shock protein 90; LDL, low-density lipoprotein; MDA, malondialdehyd; WCC, white cell count.

Figure 3

Increased eHsp90 secretion in a…

Figure 3

Increased eHsp90 secretion in a vascular endothelial cell model of oxidative injury in…

Figure 3
Increased eHsp90 secretion in a vascular endothelial cell model of oxidative injury in vitro. A CCK-8 assay (A) was used to detect cell viability in HUVECs treated with different concentrations of H2O2 for 2, 4, 6, 8, and 24 hours (n=3). The levels of MDA (B) and SOD (C) were measured with assay kits (n=3). HUVECs were treated with H2O2 (100 µM, 200 µM, and 300 µM) for 24 hours, and then the intracellular levels of ROS (D), mitochondrial ROS (E), and 8-oxoG (F) and the extracellular levels of ET-1 (G) and MCP-1 (H) were detected (n=3). (I) Western blot analysis concentrated medium and total cell extracts from HUVECs cultured with the indicated concentration of H2O2. ImageJ software was used to determine the relative intensities of extracellular and intracellular Hsp90α and Hsp90β bands (n=3). (J) Extracellular and intracellular Hsp90α and Hsp90β expressions were measured after H2O2 stimulation for different durations (n=3). (K) Western blot analysis was performed to assess the expression of related proteins in HUVECs pretreated with 17AAG and then exposed to H2O2 (n=3). (L) qPCR was employed to observe the respective Hsp90α and Hsp90β mRNA levels after HUVECs were stimulated with H2O2 and/or 17AAG for 24 hours (n=3). (M) Representative confocal images of Hsp90α subunit localization in endothelial cells after 24 hours of H2O2 stimulation are shown (n=3). All data represent mean±SD of three biological replicates. Differences between groups were analyzed by one-way ANOVA and the Dunnett test, according to the data features. *P<0.05,**P<0.01,***P<0.001 ****P<0.0001 versus control. 17AAG,17-allyamino-17-demethoxygeldanamycin; ANOVA, analysis of variance; CCK-8, Cell Counting Kit-8; Ctrl, control; DAPI, 4',6-diamidino-2-phenylindole; eHsp90, extracellular heat shock protein 90; ET-1, endothelin 1; H2O2, hydrogen peroxide; Hsp90, heat shock protein 90; HUVECs, human umbilical vein endothelial cells; MCP-1, monocyte chemotactic protein 1; MDA, malondialdehyd; mRNA, messenger RNA; 8-oxoG, 8-oxoguanine; qPCR, quantitative real-time PCR; ROS, reactive oxygen species; SOD, superoxide dismutase.

Figure 4

eHsp90α enhanced the inflammatory injury…

Figure 4

eHsp90α enhanced the inflammatory injury state of endothelial cells and recruited monocytes through…

Figure 4
eHsp90α enhanced the inflammatory injury state of endothelial cells and recruited monocytes through LRP1 receptors. Extracellular ET-1 (A) and MCP-1 (B) expressions were measured after hrHsp90α stimulation at different concentrations and durations (n=3). The expression of ET-1 (C) in endothelial cell-CM treated with H2O2 after 17AAG or 1G6-D7 pretreatment (n=3). Representative images with quantification of the results for a THP-1 cell Transwell migration assay in the presence of H2O2-treated and/or 17AAG-treated endothelial cell CM (D) and different reagents (E) (n=5). LRP1 and p-Akt expressions (F) were measured after hrHsp90α stimulation for different durations (n=3). All data represent mean±SD of three biological replicates. Differences between groups were analyzed by one-way ANOVA and the Dunnett test, according to the data features. *P<0.05, **P<0.01, ***P<0.001,****P<0.0001 versus control. 17AAG, 17-allyamino-17-demethoxygeldanamycin; ANOVA, analysis of variance; CM, conditioned medium; Ctrl, control; eHsp90, extracellular Hsp90; ET-1, endothelin 1; H2O2, hydrogen peroxide; hrHsp90, human recombinant Hsp90; Hsp90, heat shock protein 90; LRP1, low-denisity lipoprotein receptor-related protein 1; MCP-1, monocyte chemotactic protein 1.
Figure 2
Figure 2
Multivariate logistic regression model and diagnostic efficacy of Hsp90α and Hsp90β for DLEAD. Histopathological changes in blood vessels. Multivariate logistic regression analysis (A): a forest plot obtained from a multiple logistic regression model as OR with 95% CI. Comparing patients with DLEAD and DM, age, Hsp90α, course, and family history were independent risk factors for the development of DLEAD. Comparing patients with DCLI and DM, age, Hsp90α, Hsp90β, and course were independent risk factors for DCLI. Receiver operating characteristic analysis of the diagnostic efficacy of Hsp90α and Hsp90β for DM and DLEAD (B). Diagnostic ability to distinguish patients with DLEAD from patients with DM. HE staining (C and E) and immunohistochemistry (D and F) (40×, 100×, 200×) of Hsp90α in the blood vessels of patients with DCLI undergoing partial amputation (n=3). CHOL, cholesterol; DCLI, diabetic critical limb ischemia; DLEAD, diabetic lower extremity arterial disease; DM, diabetes mellitus; Hb, hemoglobin; Hsp90, heat shock protein 90; LDL, low-density lipoprotein; MDA, malondialdehyd; WCC, white cell count.
Figure 3
Figure 3
Increased eHsp90 secretion in a vascular endothelial cell model of oxidative injury in vitro. A CCK-8 assay (A) was used to detect cell viability in HUVECs treated with different concentrations of H2O2 for 2, 4, 6, 8, and 24 hours (n=3). The levels of MDA (B) and SOD (C) were measured with assay kits (n=3). HUVECs were treated with H2O2 (100 µM, 200 µM, and 300 µM) for 24 hours, and then the intracellular levels of ROS (D), mitochondrial ROS (E), and 8-oxoG (F) and the extracellular levels of ET-1 (G) and MCP-1 (H) were detected (n=3). (I) Western blot analysis concentrated medium and total cell extracts from HUVECs cultured with the indicated concentration of H2O2. ImageJ software was used to determine the relative intensities of extracellular and intracellular Hsp90α and Hsp90β bands (n=3). (J) Extracellular and intracellular Hsp90α and Hsp90β expressions were measured after H2O2 stimulation for different durations (n=3). (K) Western blot analysis was performed to assess the expression of related proteins in HUVECs pretreated with 17AAG and then exposed to H2O2 (n=3). (L) qPCR was employed to observe the respective Hsp90α and Hsp90β mRNA levels after HUVECs were stimulated with H2O2 and/or 17AAG for 24 hours (n=3). (M) Representative confocal images of Hsp90α subunit localization in endothelial cells after 24 hours of H2O2 stimulation are shown (n=3). All data represent mean±SD of three biological replicates. Differences between groups were analyzed by one-way ANOVA and the Dunnett test, according to the data features. *P<0.05,**P<0.01,***P<0.001 ****P<0.0001 versus control. 17AAG,17-allyamino-17-demethoxygeldanamycin; ANOVA, analysis of variance; CCK-8, Cell Counting Kit-8; Ctrl, control; DAPI, 4',6-diamidino-2-phenylindole; eHsp90, extracellular heat shock protein 90; ET-1, endothelin 1; H2O2, hydrogen peroxide; Hsp90, heat shock protein 90; HUVECs, human umbilical vein endothelial cells; MCP-1, monocyte chemotactic protein 1; MDA, malondialdehyd; mRNA, messenger RNA; 8-oxoG, 8-oxoguanine; qPCR, quantitative real-time PCR; ROS, reactive oxygen species; SOD, superoxide dismutase.
Figure 4
Figure 4
eHsp90α enhanced the inflammatory injury state of endothelial cells and recruited monocytes through LRP1 receptors. Extracellular ET-1 (A) and MCP-1 (B) expressions were measured after hrHsp90α stimulation at different concentrations and durations (n=3). The expression of ET-1 (C) in endothelial cell-CM treated with H2O2 after 17AAG or 1G6-D7 pretreatment (n=3). Representative images with quantification of the results for a THP-1 cell Transwell migration assay in the presence of H2O2-treated and/or 17AAG-treated endothelial cell CM (D) and different reagents (E) (n=5). LRP1 and p-Akt expressions (F) were measured after hrHsp90α stimulation for different durations (n=3). All data represent mean±SD of three biological replicates. Differences between groups were analyzed by one-way ANOVA and the Dunnett test, according to the data features. *P<0.05, **P<0.01, ***P<0.001,****P<0.0001 versus control. 17AAG, 17-allyamino-17-demethoxygeldanamycin; ANOVA, analysis of variance; CM, conditioned medium; Ctrl, control; eHsp90, extracellular Hsp90; ET-1, endothelin 1; H2O2, hydrogen peroxide; hrHsp90, human recombinant Hsp90; Hsp90, heat shock protein 90; LRP1, low-denisity lipoprotein receptor-related protein 1; MCP-1, monocyte chemotactic protein 1.

References

    1. International Diabetes Federation . IDF diabetes atlas. Brussels, Belgium: International Diabetes Federation, 2019.
    1. Shah AD, Langenberg C, Rapsomaniki E, et al. . Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol 2015;3:105–13. 10.1016/S2213-8587(14)70219-0
    1. Tousoulis D, Kampoli A-M, Stefanadis C. Diabetes mellitus and vascular endothelial dysfunction: current perspectives. Curr Vasc Pharmacol 2012;10:19–32. 10.2174/157016112798829797
    1. Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab 2013;17:20–33. 10.1016/j.cmet.2012.11.012
    1. Shah MS, Brownlee M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res 2016;118:1808–29. 10.1161/CIRCRESAHA.116.306923
    1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999;340:115–26. 10.1056/NEJM199901143400207
    1. Lei H, Romeo G, Kazlauskas A. Heat shock protein 90alpha-dependent translocation of annexin II to the surface of endothelial cells modulates plasmin activity in the diabetic rat aorta. Circ Res 2004;94:902–9. 10.1161/01.RES.0000124979.46214.E3
    1. Lazaro I, Oguiza A, Recio C, et al. . Targeting Hsp90 ameliorates nephropathy and atherosclerosis through suppression of NF-κB and STAT signaling pathways in diabetic mice. Diabetes 2015;64:3600–13. 10.2337/db14-1926
    1. Kim J, Jang S-W, Park E, et al. . The role of heat shock protein 90 in migration and proliferation of vascular smooth muscle cells in the development of atherosclerosis. J Mol Cell Cardiol 2014;72:157–67. 10.1016/j.yjmcc.2014.03.008
    1. Madrigal-Matute J, López-Franco O, Blanco-Colio LM, et al. . Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. Cardiovasc Res 2010;86:330–7. 10.1093/cvr/cvq046
    1. Jayaprakash P, Dong H, Zou M, et al. . Hsp90α and Hsp90β together operate a hypoxia and nutrient paucity stress-response mechanism during wound healing. J Cell Sci 2015;128:1475–80. 10.1242/jcs.166363
    1. Tsen F, Bhatia A, O'Brien K, et al. . Extracellular heat shock protein 90 signals through subdomain II and the NPVY motif of LRP-1 receptor to Akt1 and Akt2: a circuit essential for promoting skin cell migration in vitro and wound healing in vivo. Mol Cell Biol 2013;33:4947–59. 10.1128/MCB.00559-13
    1. Li W, Tsen F, Sahu D, et al. . Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally. Int Rev Cell Mol Biol 2013;303:203–35. 10.1016/B978-0-12-407697-6.00005-2
    1. Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. . Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215–22. 10.1016/S0140-6736(10)60484-9
    1. UK Prospective Diabetes Study Group . UK prospective diabetes study (UKPDS). VIII. study design, progress and performance. Diabetologia 1991;34:877–90.
    1. Hennion DR, Siano KA. Diagnosis and treatment of peripheral arterial disease. Am Fam Physician 2013;88:306–10.
    1. He X, Hu X, Ma X, et al. . Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2017;16:77. 10.1186/s12933-017-0559-x
    1. Shalash MAM, Rohoma KH, Kandil NS, et al. . Serum sclerostin level and its relation to subclinical atherosclerosis in subjects with type 2 diabetes. J Diabetes Complications 2019;33:592–7. 10.1016/j.jdiacomp.2019.04.012
    1. Wang X, Shi J, Lu B, et al. . Circulating heat shock protein 27 as a novel marker of subclinical atherosclerosis in type 2 diabetes: a cross-sectional community-based study. BMC Cardiovasc Disord 2020;20:198. 10.1186/s12872-020-01456-7
    1. Bellini S, Barutta F, Mastrocola R, et al. . Heat shock proteins in vascular diabetic complications: review and future perspective. Int J Mol Sci 2017;18:2709. 10.3390/ijms18122709
    1. Jakhotia S, Sivaprasad M, Shalini T, et al. . Circulating levels of Hsp27 in microvascular complications of diabetes: prospects as a biomarker of diabetic nephropathy. J Diabetes Complications 2018;32:221–5. 10.1016/j.jdiacomp.2017.10.004
    1. Shamaei-Tousi A, Stephens JW, Bin R, et al. . Association between plasma levels of heat shock protein 60 and cardiovascular disease in patients with diabetes mellitus. Eur Heart J 2006;27:1565–70. 10.1093/eurheartj/ehl081
    1. Sayed KM, Mahmoud AA. Heat shock protein-70 and hypoxia inducible factor-1α in type 2 diabetes mellitus patients complicated with retinopathy. Acta Ophthalmol 2016;94:e361–6. 10.1111/aos.12919
    1. Ocaña GJ, Sims EK, Watkins RA, et al. . Analysis of serum Hsp90 as a potential biomarker of β cell autoimmunity in type 1 diabetes. PLoS One 2019;14:e0208456. 10.1371/journal.pone.0208456
    1. Businaro R, Profumo E, Tagliani A, et al. . Heat-Shock protein 90: a novel autoantigen in human carotid atherosclerosis. Atherosclerosis 2009;207:74–83. 10.1016/j.atherosclerosis.2009.04.026
    1. Zhu Y, Xian X, Wang Z, et al. . Research progress on the relationship between atherosclerosis and inflammation. Biomolecules 2018;8:80. 10.3390/biom8030080
    1. Knapp M, Tu X, Wu R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. Acta Pharmacol Sin 2019;40:1–8. 10.1038/s41401-018-0042-6
    1. Mudau M, Genis A, Lochner A, et al. . Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr 2012;23:222–31. 10.5830/CVJA-2011-068
    1. Ning D-S, Ma J, Peng Y-M, et al. . Apolipoprotein A-I mimetic peptide inhibits atherosclerosis by increasing tetrahydrobiopterin via regulation of GTP-cyclohydrolase 1 and reducing uncoupled endothelial nitric oxide synthase activity. Atherosclerosis 2021;328:83–91. 10.1016/j.atherosclerosis.2021.05.019
    1. Frostegård J, Zhang Y, Sun J, et al. . Oxidized Low-Density Lipoprotein (OxLDL)-Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: microRNA let-7c Is Integral to the Effect. J Am Heart Assoc 2016;5:e003976. 10.1161/JAHA.116.003976
    1. Rahman M, Steuer J, Gillgren P, et al. . Induction of dendritic cell-mediated activation of T cells from atherosclerotic plaques by human heat shock protein 60. J Am Heart Assoc 2017;6:e006778. 10.1161/JAHA.117.006778
    1. Liu A, Ming JY, Fiskesund R, et al. . Induction of dendritic cell-mediated T-cell activation by modified but not native low-density lipoprotein in humans and inhibition by annexin A5: involvement of heat shock proteins. Arterioscler Thromb Vasc Biol 2015;35:197–205. 10.1161/ATVBAHA.114.304342
    1. Profumo E, Buttari B, Tinaburri L, et al. . Oxidative stress induces Hsp90 upregulation on the surface of primary human endothelial cells: role of the antioxidant 7,8-dihydroxy-4-methylcoumarin in preventing Hsp90 exposure to the immune system. Oxid Med Cell Longev 2018;2018:1–9. 10.1155/2018/2373167
    1. Bäck M, Yurdagul A, Tabas I, et al. . Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol 2019;16:389-406. 10.1038/s41569-019-0169-2
    1. Low Wang CC, Hess CN, Hiatt WR, et al. . Clinical Update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation 2016;133:2459–502. 10.1161/CIRCULATIONAHA.116.022194
    1. Ambade A, Catalano D, Lim A, et al. . Inhibition of heat shock protein 90 alleviates steatosis and macrophage activation in murine alcoholic liver injury. J Hepatol 2014;61:903–11. 10.1016/j.jhep.2014.05.024
    1. Needham LA, Davidson AH, Bawden LJ, et al. . Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs. J Pharmacol Exp Ther 2011;339:132–42. 10.1124/jpet.111.183640
    1. Kansakar U, Jankauskas SS, Gambardella J, et al. . Targeting the phenotypic switch of vascular smooth muscle cells to tackle atherosclerosis. Atherosclerosis 2021;324:117–20. 10.1016/j.atherosclerosis.2021.03.034
    1. Madrigal-Matute J, Fernandez-Garcia CE, Gomez-Guerrero C, et al. . Hsp90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis. Cardiovasc Res 2012;95:116–23. 10.1093/cvr/cvs158

Source: PubMed

3
Sottoscrivi